Posts by: Patricia Inacio PhD

Patricia Inacio PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

February 4, 2021February 4, 2021

Uveitis Leads to Poorer Vision in JIA Children, Affecting Life Quality

News

Uveitis, a form of eye inflammation, worsens vision and vision-related quality of life among children with juvenile idiopathic arthritis (JIA), according to a large questionnaire study. Results also showed worse ... Read more

January 21, 2021January 21, 2021

Celecoxib Capsules, Generic of Celebrex, Approved for Pain, Inflammation

News

The U.S. Food and Drug Administration (FDA) has approved celecoxib capsules — a generic form of Pfizer’s Celebrex — to treat inflammation and pain in juvenile idiopathic arthritis (JIA) and ... Read more

October 22, 2020October 22, 2020

Corticosteroids Injection Near Jaw May Lessen JIA Joint Inflammation

News

A localized injection of corticosteroids into the temporomandibular joints (TMJs) — the joints near the ears where the jawbone connects to the skull — may ease inflammation and help with ... Read more

September 24, 2020September 24, 2020

Lower Doses of Ilaris Can Maintain Clinical Remission in Systemic-onset JIA, Trial Shows

News

Treatment with Ilaris (canakinumab) at doses lower than the one recommended might be enough to maintain clinical remission in people with systemic juvenile idiopathic arthritis (sJIA), clinical data show. Yet, as ... Read more

June 12, 2020June 12, 2020

Enbrel Biosimilar Nepexto Approved in Europe for JIA, Other Inflammatory Disorders

News

The European Commission has approved Nepexto, a biosimilar of Enbrel (etanercept), for the treatment of juvenile idiopathic arthritis and other inflammatory disorders. Nepexto is expected to be available to patients in the European Union ... Read more

May 29, 2020May 29, 2020

Nearly One-fifth of Infections Opportunistic in JIA Children on Immunosuppressants, Study Reports

News

Close to one-fifth of infections in children with juvenile idiopathic arthritis (JIA) on immunosuppressants are caused by opportunistic pathogens — such as microorganisms that take advantage of weakened immune system ... Read more

December 3, 2019December 3, 2019

FDA Approves RediTrex, an Injectable Form of Methotrexate, for JIA Treatment

News

The U.S. Food and Drug Administration (FDA) has approved RediTrex, an injectable form of methotrexate, for the treatment of juvenile idiopathic arthritis (JIA), active rheumatoid arthritis, and severe psoriasis. Methotrexate ... Read more

October 22, 2019October 22, 2019

Uveitis Affects Almost 20% of Children with Juvenile Idiopathic Arthritis, Study Reports

News

Uveitis — inflammation of the eye — affects almost 20% of children with juvenile idiopathic arthritis (JIA), according to a study. Findings revealed that while chronic uveitis affects mostly girls ... Read more

October 18, 2019October 18, 2019

Nearly 60% of Americans Struggle to Afford Medications for Rheumatic Diseases, National Survey Finds

News

Nearly 60% of respondents in a national survey of people with juvenile arthritis and other rheumatic diseases reported struggling to afford their medications in the past year. The online survey, ... Read more

July 26, 2019July 26, 2019

Levels of Chemokines CXCL8, CXCL10 May Help Predict Risk for JIA, RA, Study Suggests

News

Blood levels of chemokines CXCL8 and CXCL10 — two signalling molecules— may help predict risk for juvenile idiopathic arthritis and rheumatoid arthritis, according to a study in a group of ... Read more